找回密碼
 To register

QQ登錄

只需一步,快速開始

掃一掃,訪問微社區(qū)

打印 上一主題 下一主題

Titlebook: Leading Pharmaceutical Innovation; Trends and Drivers f Oliver Gassmann,Gerrit Reepmeyer,Maximilian Zedtwi Book 20041st edition Springer-Ve

[復(fù)制鏈接]
查看: 7295|回復(fù): 42
樓主
發(fā)表于 2025-3-21 18:27:37 | 只看該作者 |倒序瀏覽 |閱讀模式
書目名稱Leading Pharmaceutical Innovation
副標(biāo)題Trends and Drivers f
編輯Oliver Gassmann,Gerrit Reepmeyer,Maximilian Zedtwi
視頻videohttp://file.papertrans.cn/583/582421/582421.mp4
概述The book is based on the three most important challenges in pharmaceutical innovation: productivity dilemma, new technology trends, globalization and outsourcing.Due to the CTO-roundtable with 14 sele
圖書封面Titlebook: Leading Pharmaceutical Innovation; Trends and Drivers f Oliver Gassmann,Gerrit Reepmeyer,Maximilian Zedtwi Book 20041st edition Springer-Ve
描述Pharmaceutical innovation is like gambling at roulette, only the stakes are higher. Considerably higher, since the most recent estimates put the costs of drug development at US$ 800 million to US$ 1 billion - per drug! This is equivalent to the price tag of the Empire State Building, when it was for sale a few years ago. In 2001, the major US and European pharmaceutical companies invested more than US$ 30 billion in R&D, at a higher R&D- to-sales ratio than virtually any other industry, including chemicals, auto- mobiles, electronics, aerospace, and computers. Delivering a blockbuster drug is the Holy Grail for any pharmaceutical company. But in the last decade the rules of developing blockbusters seem to have changed. On the one hand, more sophisticated screening technolo- gies, genetic engineering, and expanding networks with biotechnology companies increase the probability of commercial success. Critical success factors include the discovery phase and a stronger outside-in orientation in the early innovation phase. After the implosion of the high-tech stock mar- ket, biotechnology and other technology-driven opportunities may have lost some of their attractiveness for big pharma
出版日期Book 20041st edition
關(guān)鍵詞Drug Discovery; Forschung & Entwicklung; Globalization; Innovation Management; Pharmaceuticals; Productiv
版次1
doihttps://doi.org/10.1007/978-3-540-24781-4
isbn_ebook978-3-540-24781-4
copyrightSpringer-Verlag Berlin Heidelberg 2004
The information of publication is updating

書目名稱Leading Pharmaceutical Innovation影響因子(影響力)




書目名稱Leading Pharmaceutical Innovation影響因子(影響力)學(xué)科排名




書目名稱Leading Pharmaceutical Innovation網(wǎng)絡(luò)公開度




書目名稱Leading Pharmaceutical Innovation網(wǎng)絡(luò)公開度學(xué)科排名




書目名稱Leading Pharmaceutical Innovation被引頻次




書目名稱Leading Pharmaceutical Innovation被引頻次學(xué)科排名




書目名稱Leading Pharmaceutical Innovation年度引用




書目名稱Leading Pharmaceutical Innovation年度引用學(xué)科排名




書目名稱Leading Pharmaceutical Innovation讀者反饋




書目名稱Leading Pharmaceutical Innovation讀者反饋學(xué)科排名




單選投票, 共有 0 人參與投票
 

0票 0%

Perfect with Aesthetics

 

0票 0%

Better Implies Difficulty

 

0票 0%

Good and Satisfactory

 

0票 0%

Adverse Performance

 

0票 0%

Disdainful Garbage

您所在的用戶組沒有投票權(quán)限
沙發(fā)
發(fā)表于 2025-3-21 21:18:35 | 只看該作者
The Science and Technology Challenge: How to Find New Drugs,company would ever be able to enter the pharmaceutical industry and to compete with the industry’s giants (see Robbins-Roth 2001). However, some entrepreneurs were not impressed with this challenge and created an entirely new industry — the biotechnology industry. Besides an innovative management ap
板凳
發(fā)表于 2025-3-22 01:57:50 | 只看該作者
The Pipeline Management Challenge: How to Shape the Innovation-Flow,cancer, 120 for heart diseases and strokes, 26 for Alzheimer’s disease, 25 for diabetes, and more than 200 for special needs of children. In order to maintain or exceed double-digit growth expectations, pharmaceutical companies are required to deliver between two and four new drugs every year. Given
地板
發(fā)表于 2025-3-22 05:57:53 | 只看該作者
5#
發(fā)表于 2025-3-22 12:29:16 | 只看該作者
Appendices,end of the industry average; this has enabled Novartis to invest significantly in organic growth. In addition, Novartis consolidated activities with the divestment of non-core businesses. As a first and significant step, the company spun-off its CHF 8 billion specialty chemicals business Ciba SC in
6#
發(fā)表于 2025-3-22 15:08:55 | 只看該作者
7#
發(fā)表于 2025-3-22 19:49:03 | 只看該作者
Oliver Gassmann,Gerrit Reepmeyer,Maximilian von Zedtwitzreets, tripping and falling, and people laughing. Such a reaction is one of the enduring puzzles of humour philosophy—that is, why would a scenario otherwise so pathetic activate sensations of the comic, and how should humour be classified in this and other regards. Other scenarios that are actually
8#
發(fā)表于 2025-3-22 22:27:10 | 只看該作者
9#
發(fā)表于 2025-3-23 03:51:42 | 只看該作者
10#
發(fā)表于 2025-3-23 07:18:02 | 只看該作者
Oliver Gassmann,Gerrit Reepmeyer,Maximilian von Zedtwitz existence-spheres is not as strange as it might at first appear. To do this, I shall draw upon M. Jamie Ferreira’s work on the role of the imagination in ethical and religious transitions.. Taking up a strand of the argument of Chapter 2, I shall consider the idea that the chief instrument of exist
 關(guān)于派博傳思  派博傳思旗下網(wǎng)站  友情鏈接
派博傳思介紹 公司地理位置 論文服務(wù)流程 影響因子官網(wǎng) 吾愛論文網(wǎng) 大講堂 北京大學(xué) Oxford Uni. Harvard Uni.
發(fā)展歷史沿革 期刊點評 投稿經(jīng)驗總結(jié) SCIENCEGARD IMPACTFACTOR 派博系數(shù) 清華大學(xué) Yale Uni. Stanford Uni.
QQ|Archiver|手機版|小黑屋| 派博傳思國際 ( 京公網(wǎng)安備110108008328) GMT+8, 2025-10-5 06:39
Copyright © 2001-2015 派博傳思   京公網(wǎng)安備110108008328 版權(quán)所有 All rights reserved
快速回復(fù) 返回頂部 返回列表
搜索| 宁晋县| 桂林市| 南宫市| 鄂伦春自治旗| 岳池县| 滦南县| 龙游县| 应城市| 翁源县| 赫章县| 台中县| 曲周县| 彩票| 阜宁县| 高碑店市| 贵南县| 内江市| 当阳市| 牡丹江市| 隆化县| 施秉县| 齐齐哈尔市| 武定县| 华安县| 册亨县| 连云港市| 五家渠市| 大连市| 莆田市| 崇州市| 体育| 泉州市| 黑水县| 迁西县| 克东县| 辉县市| 监利县| 西华县| 古田县| 平遥县|